c
h
p
e
r
overview
success
manag
infect
kidney
transplant
recipi
complic
factor
relat
immun
statu
host
epidemiolog
infect
transplant
recipi
suscept
broad
spectrum
infecti
pathogen
manifest
diminish
sign
symptom
invas
infect
thu
diagnosi
infect
difficult
transplant
immunolog
normal
individu
interact
infect
immunosuppress
immun
function
play
complex
environ
multipl
simultan
process
infect
graft
reject
may
contribut
clinic
present
immunocompromis
patient
toler
invas
establish
infect
poorli
high
morbid
mortal
lend
urgenc
need
earli
specif
diagnosi
guid
antimicrobi
therapi
given
tlymphocyt
dysfunct
inher
transplant
immunosuppress
viral
infect
particular
increas
viral
infect
contribut
graft
dysfunct
graft
reject
system
ill
also
enhanc
risk
opportunist
infect
eg
pneumocysti
aspergillu
viral
mediat
cancer
risk
infect
kidney
transplant
recipi
determin
interact
two
key
factor
epidemiolog
exposur
patient
includ
time
intens
virul
organ
experienc
patient
net
state
immunosuppress
conceptu
measur
factor
contribut
host
risk
infect
import
infecti
exposur
determin
abil
host
deal
effect
pathogen
thu
diabet
greater
risk
bacteri
skin
infect
nondiabet
calcineurin
inhibitor
therapi
understand
risk
factor
transplant
recipi
allow
develop
differenti
diagnos
infecti
syndrom
develop
prevent
strategi
prophylaxi
vaccin
appropri
individu
risk
infect
epidemiolog
exposur
import
divid
four
overlap
categori
donorderiv
infect
recipientderiv
infect
communityderiv
exposur
nosocomi
exposur
tabl
infect
deriv
donor
tissu
activ
recipi
uncommon
recogn
among
import
infecti
exposur
transplant
infect
latent
eg
viral
parasit
wherea
other
result
activ
infect
eg
sepsi
donor
time
procur
common
pathogen
endem
organ
caus
signific
morbid
potenti
recipi
form
basi
screen
paradigm
organ
donor
type
infect
recogn
transplant
recipi
point
bacterem
fungem
infect
eg
staphylococcu
aureu
candida
speci
gramneg
bacteria
donor
time
donat
caus
local
abscess
system
bacterem
infect
may
select
adher
anastomot
site
vascular
urinari
produc
leak
mycot
aneurysm
viral
infect
ubiquit
includ
cytomegaloviru
cmv
epsteinbarr
viru
ebv
associ
particular
syndrom
morbid
immunocompromis
popul
see
section
select
infect
import
greatest
risk
infect
seroneg
immunolog
recipi
receiv
infect
graft
seroposit
donor
latent
viral
infect
virus
demonstr
acceler
progress
lymphocyt
choriomening
lymphocyt
choriomening
viru
lcmv
rabi
transplant
recipi
latent
infect
tuberculosi
toxoplasmosi
strongyloidiasi
may
activ
graft
mani
year
initi
often
unrecogn
exposur
donor
screen
transplant
limit
avail
technolog
time
avail
within
organ
deceas
donor
must
use
present
routin
evalu
donor
reli
antibodi
detect
serolog
test
common
infect
result
activ
infect
remain
undetect
seroconvers
may
occur
acut
infect
limit
suggest
achiev
benefit
transplant
organ
implant
carri
unidentifi
pathogen
risk
exhibit
cluster
donorderiv
trypanosoma
cruzi
chaga
diseas
rabi
viru
west
nile
viru
lcmv
infect
organ
transplant
recipi
molecular
assay
donor
screen
eg
human
immunodefici
viru
hiv
hepat
b
viru
hbv
hepat
c
viru
hcv
capac
reduc
window
period
exposur
develop
posit
microbiolog
assay
nucleic
acid
test
nat
instead
seroconvers
risk
falseposit
assay
given
heighten
nat
sensit
given
risk
transmiss
infect
organ
donor
recipi
certain
infect
consid
rel
contraind
organ
donat
kidney
transplant
typic
elect
surgeri
reason
avoid
donat
individu
unexplain
fever
rash
infecti
syndrom
includ
mening
enceph
common
criteria
exclus
organ
donor
list
tabl
recipientderiv
exposur
gener
reflect
colon
latent
infect
reactiv
immunosuppress
certain
common
infect
recogn
evalu
transplant
candid
includ
hbv
hcv
hiv
necessari
obtain
care
histori
prior
infect
travel
exposur
guid
prevent
strategi
empir
therapi
notabl
among
infect
mycobacteri
infect
includ
tuberculosi
strongyloidiasi
viral
infect
herp
simplex
viru
hsv
varicellazost
viru
vzv
shingl
histoplasmosi
coccidioidomycosi
paracoccidiomycosi
figur
vaccin
statu
evalu
tetanu
hbv
childhood
vaccin
influenza
pneumococcu
vaccin
previous
administ
consid
advanc
transplant
live
viru
vaccin
contraind
transplant
tabl
dietari
habit
also
consid
includ
use
well
water
cryptosporidium
uncook
meat
salmonella
listeria
unpasteur
dairi
product
listeria
common
exposur
commun
often
relat
contamin
food
water
ingest
exposur
infect
famili
member
cowork
exposur
relat
hobbi
travel
work
infect
caus
common
respiratori
virus
influenza
parainfluenza
respiratori
syncyti
viru
rsv
adenoviru
metapneumoviru
atyp
pathogen
hsv
carri
risk
viral
pneumonia
increas
risk
bacteri
fungal
superinfect
commun
contact
transfusionassoci
exposur
cmv
ebv
may
produc
sever
primari
infect
nonimmun
host
recent
remot
exposur
endem
geograph
restrict
system
mycos
blastomyc
dermatitidi
coccidioid
immiti
histoplasma
capsulatum
mycobacterium
tuberculosi
result
local
pulmonari
system
metastat
infect
asymptomat
strongyloid
stercorali
infect
may
activ
year
initi
exposur
due
immunosuppress
therapi
figur
reactiv
result
either
diarrheal
ill
parasit
migrat
hyperinfest
syndrom
character
hemorrhag
enterocol
hemorrhag
pneumonia
dissemin
infect
accompani
usual
gramneg
bacteremia
mening
gastroenter
secondari
salmonella
cryptosporidium
varieti
enter
virus
result
persist
infect
sever
prolong
diarrheal
diseas
increas
risk
primari
secondari
blood
stream
invas
metastat
infect
nosocomi
infect
increas
import
organ
signific
antimicrobi
resist
present
medic
center
includ
enterococci
resist
vancomycin
linezolid
andor
quinupristindalfopristin
methicillinresist
staphylococci
gramneg
bacteria
produc
extendedspectrum
betalactamas
esbl
fluconazoleresist
candida
speci
respiratori
viral
infect
may
acquir
medic
staff
consid
among
caus
fever
respiratori
decompens
hospit
institution
immunocompromis
individu
nosocomi
acquir
infect
investig
ascertain
sourc
prevent
subsequ
infect
net
state
immunosuppress
qualit
measur
risk
factor
infect
individu
includ
immunosuppress
medic
iatrogen
condit
standard
immunosuppress
regimen
specif
infect
occur
often
vari
predict
pattern
depend
time
elaps
sinc
transplant
figur
primarili
reflect
chang
risk
factor
time
includ
surgeri
hospit
taper
immunosuppress
acut
chronic
reject
exposur
infect
commun
predict
pattern
infect
chang
alter
immunosuppress
regimen
pulsedos
steroid
intensif
graft
reject
intercurr
viral
infect
neutropenia
drug
toxic
graft
dysfunct
signific
epidemiolog
exposur
travel
food
timelin
remain
use
start
point
differenti
diagnosi
infect
transplant
although
alter
introduct
new
immunosuppress
agent
pattern
use
includ
reduc
use
corticosteroid
calcineurin
inhibitor
increas
use
antibodybas
induct
therapi
sirolimu
routin
antimicrobi
prophylaxi
improv
molecular
assay
antimicrobi
resist
transplant
hivinfect
hcvinfect
individu
broader
epidemiolog
exposur
work
travel
figur
show
three
overlap
period
risk
infect
transplant
associ
differ
pattern
common
pathogen
follow
periop
period
approxim
week
transplant
reflect
surgic
technic
complic
nosocomi
exposur
period
month
transplant
depend
rapid
taper
immunosuppress
use
antilymphocyt
induct
therapi
deploy
prophylaxi
reflect
intens
immunosuppress
viral
activ
opportunist
infect
period
beyond
first
year
transplant
reflect
communityacquir
exposur
unusu
pathogen
base
level
mainten
immunosuppress
timelin
use
varieti
way
establish
differenti
diagnosi
transplant
patient
suspect
infect
provid
clue
presenc
excess
environment
hazard
individu
either
within
hospit
commun
serv
guid
design
prevent
antimicrobi
strategi
infect
occur
outsid
usual
period
unusu
sever
suggest
either
excess
epidemiolog
hazard
excess
immunosuppress
prevent
infect
must
link
risk
infect
variou
time
transplant
tabl
outlin
routin
prevent
strategi
massachusett
gener
hospit
strategi
serv
delay
onset
infect
face
epidemiolog
pressur
use
antimicrobi
prophylaxi
vaccin
behavior
modif
eg
routin
hand
wash
advic
dig
garden
without
mask
may
result
shift
right
infect
timelin
unless
intens
immunosuppress
reduc
immun
develop
first
month
transplant
three
type
infect
occur
first
type
infect
colon
present
recipi
transplant
emerg
set
surgeri
immunosuppress
pretransplant
pneumonia
vascular
access
infect
common
exampl
type
infect
colon
recipi
resist
organ
infect
intraven
cathet
surgic
drain
also
common
eg
methicillinresist
staphylococcu
aureu
infect
control
erad
degre
possibl
transplant
second
type
earli
infect
donorderiv
type
may
nosocomi
deriv
resist
gramneg
bacilli
aureu
candida
speci
secondari
system
infect
donor
eg
line
infect
contamin
organ
procur
process
rare
infect
transmit
donor
recipi
may
emerg
earlier
predict
eg
tuberculosi
histoplasmosi
recent
cluster
donorderiv
infect
due
unfortun
time
donor
acquir
acut
infect
hiv
west
nile
viru
rabi
prior
death
due
unrel
caus
third
common
sourc
infect
earli
period
relat
surgic
procedur
transplant
infect
includ
surgic
wound
infect
pneumonia
aspir
bacteremia
secondari
vascular
access
surgic
drainag
cathet
urinari
tract
infect
infect
fluid
collect
leak
vascular
urinari
anastomos
lymphocel
nosocomi
infect
may
carri
antimicrobialresist
pathogen
observ
nonimmunosuppress
patient
undergo
compar
surgeri
given
immunosuppress
sign
infect
may
subtl
howev
sever
durat
usual
greater
thu
bowel
perfor
may
clinic
silent
mark
rise
white
blood
cell
count
graft
dysfunct
technic
skill
surgeon
meticul
postop
care
ie
wound
care
proper
mainten
time
remov
endotrach
tube
vascular
access
devic
drainag
cathet
determin
risk
infect
anoth
common
infect
clostridium
difficil
coliti
limit
periop
antibiot
prophylaxi
ie
singl
dose
hour
antibiot
cefazolin
amoxicillinclavulan
usual
adequ
addit
coverag
requir
known
risk
factor
eg
prior
colon
methicillinresist
aureu
one
singlestrength
tmpsmx
tablet
contain
mg
trimethoprim
mg
sulfamethoxazol
oral
daili
minimum
month
posttransplant
patient
infect
cytomegaloviru
cmv
chronic
reject
recurr
infect
maintain
lifelong
prophylaxi
thriceweekli
regimen
tmpsmx
prevent
pcp
prevent
infect
eg
urinari
tract
infect
nocardia
listeria
toxoplasma
gastrointestin
pulmonari
infect
patient
proven
toler
tmpsmx
altern
regimen
includ
combin
atovaquon
mg
oral
daili
meal
plu
levofloxacin
mg
oral
daili
equival
fluoroquinolon
without
anaerob
activ
pentamidin
mg
intraven
inhal
everi
week
dapson
mg
oral
daili
twice
weekli
without
pyrimethamin
agent
toxic
must
consid
eg
hemolysi
host
dapson
none
altern
program
offer
broad
protect
tmpsmx
cytomegaloviru
antivir
prophylaxi
pancrea
transplant
addit
periop
prophylaxi
yeast
common
use
fluconazol
mind
potenti
increas
sirolimu
calcineurin
inhibitor
level
use
azol
antifung
agent
opportunist
infect
notabl
absenc
first
month
transplant
even
though
daili
dose
immunosuppress
drug
may
greatest
time
implic
observ
import
suggest
daili
dose
immunosuppress
drug
import
rather
cumul
dose
drug
area
curv
determin
true
state
immunosuppress
net
state
immunosuppress
great
enough
support
occurr
opportunist
infect
unless
exposur
excess
occurr
singl
case
opportunist
infect
period
trigger
epidemiolog
investig
environment
hazard
second
phase
infect
origin
month
alter
two
main
factor
includ
success
use
prophylaxi
monitor
program
cmv
herpesvirus
pneumocysti
urinari
tract
infect
hbv
intensif
immunosuppress
use
potent
agent
antibodybas
therapi
prolong
effect
immun
function
tabl
infect
transplant
recipi
month
transplant
one
three
caus
infect
perisurg
period
includ
relaps
c
difficil
coliti
inadequ
treat
pneumonia
infect
relat
technic
problem
eg
urin
leak
lymphocel
ureter
strictur
hematoma
fluid
collect
set
gener
requir
drainag
viral
infect
includ
cmv
hsv
shingl
vzv
human
herpesviru
hhv
ebv
hepat
hbv
hcv
hiv
group
virus
uniqu
infect
lifelong
tissueassoci
often
transmit
allograft
seroposit
donor
virus
system
immunosuppress
predispos
opportunist
infect
acceler
infect
hcv
predispos
graft
reject
herpesvirus
promin
given
import
tcell
function
antivir
control
disproportion
degre
tcell
inhibit
immunosuppress
regimen
common
viral
pathogen
period
includ
bk
polyomaviru
associ
allograft
dysfunct
polyomavirusassoci
nephropathi
pvan
communityacquir
respiratori
virus
adenoviru
influenza
parainfluenza
respiratori
syncyti
viru
metapneumoviru
superinfect
viral
infect
host
common
opportunist
infect
secondari
pneumocysti
jiroveci
listeria
monocytogen
toxoplasma
gondii
nocardia
aspergillu
agent
period
stage
also
set
emerg
subgroup
patient
chronic
neer
well
patient
requir
higher
averag
immunosuppress
maintain
graft
function
prolong
untreat
viral
infect
opportunist
infect
predict
longterm
suscept
infect
third
phase
discuss
patient
may
benefit
prolong
lifelong
prophylaxi
antibacteri
antifung
antivir
combin
prevent
lifethreaten
infect
specif
opportunist
infect
occur
reflect
specif
immunosuppress
regimen
use
individu
epidemiolog
presenc
absenc
immunomodul
viral
infect
viral
pathogen
reject
respons
febril
episod
occur
period
period
anticmv
strategi
trimethoprimsulfamethoxazol
prophylaxi
effect
decreas
risk
infect
trimethoprim
sulfamethoxazol
prophylaxi
effect
prevent
pneumocysti
pneumonia
reduc
incid
urinari
tract
infect
urosepsi
listeria
monocytogen
mening
nocardia
speci
infect
gondii
recipi
underw
tranplant
month
previous
divid
three
group
term
infect
risk
transplant
recipi
technic
good
procedur
satisfactori
allograft
function
reduc
immunosuppress
absenc
chronic
viral
infect
patient
resembl
gener
commun
term
infect
risk
communityacquir
respiratori
virus
constitut
major
risk
occasion
patient
develop
primari
cmv
infect
social
acquir
infect
relat
underli
diseas
eg
skin
infect
diabet
second
group
patient
chronic
viral
infect
may
produc
endorgan
damag
eg
bk
polyomaviru
lead
fibrosi
hcv
lead
cryoglobulinemia
cirrhosi
cmv
chronic
graft
reject
malign
eg
posttransplant
lymphoprolif
diseas
ptld
secondari
ebv
skin
anogenit
cancer
relat
papillomavirus
absenc
specif
effect
antivir
therapi
patient
often
suffer
graft
reject
result
reduc
intens
immunosuppress
third
group
patient
unsatisfactori
allograft
function
suffer
ravag
renal
dysfunct
often
despit
intensifi
immunosuppress
use
preserv
graft
function
recent
result
underli
diseas
progress
atherosclerosi
iga
diabet
calcineurin
inhibitor
toxic
humor
well
cellular
graft
reject
result
patient
overimmunosuppress
rel
risk
infect
patient
may
benefit
lifetim
mainten
trimethoprimsulfamethoxazol
prophylaxi
often
fluconazol
prophylaxi
group
one
also
consid
organ
often
associ
immun
dysfunct
acquir
immunodefici
syndrom
aid
bartonella
rhodococcu
cryptosporidium
microsporidia
invas
fungal
pathogen
aspergillu
zygomycet
dematiacea
pigment
mold
even
minim
clinic
sign
symptom
warrant
care
evalu
group
highrisk
patient
guidelin
pretranspl
screen
subject
sever
public
includ
consensu
confer
immunocompromis
host
societi
american
societi
transplant
clinic
practic
guidelin
evalu
kidney
transplant
candid
american
societi
transplant
surgeon
clinic
practic
guidelin
evalu
live
kidney
transplant
donor
crucial
featur
screen
deceas
organ
donor
time
limit
use
organ
must
procur
implant
microbiolog
assess
complet
major
infect
must
exclud
appropri
cultur
sampl
must
obtain
futur
refer
result
bacteremia
fungemia
may
detect
transplant
perform
infect
gener
result
transmiss
infect
long
infect
adequ
treat
term
use
antimicrobi
agent
organ
suscept
time
recipi
tissu
bacterem
donor
mean
day
effect
therapi
transplant
seem
adequ
prevent
transmiss
suscept
pathogen
longer
cours
therapi
recipi
prefer
target
known
donorderiv
pathogen
bacteri
mening
must
treat
antibiot
penetr
cerebrospin
fluid
organ
procur
individu
unidentifi
untreat
caus
meningoenceph
sepsi
use
organ
donor
donorderiv
infect
due
candida
speci
result
contamin
candidemia
time
procur
requir
suscept
test
isol
prolong
treatment
week
effect
agent
avoid
pyelonephr
abscess
format
mycot
aneurysm
fungemia
recipi
vascular
involv
candida
speci
recipi
requir
least
week
therapi
certain
acut
infect
cmv
hsv
ebv
hiv
hcv
may
undetect
period
antibodi
format
viral
nucleic
acid
detect
assay
prefer
sensit
likewis
donor
clinic
social
medic
histori
essenti
reduc
risk
infect
presenc
known
infect
infect
must
treat
procur
possibl
sever
recent
cluster
donorderiv
infect
shown
risk
infect
secondari
previous
unrecogn
pathogen
includ
lymphocyt
choriomening
viru
chaga
diseas
hsv
addit
common
pathogen
major
exclus
criteria
outlin
tabl
contrast
abovedescrib
scenario
live
donor
procedur
consid
elect
evalu
complet
infect
treat
procedur
interim
histori
must
taken
time
surgeri
assess
presenc
new
infect
sinc
initi
donor
evalu
intercurr
infect
flulik
ill
headach
confus
myalgia
cough
might
harbing
import
infect
west
nile
viru
sever
acut
respiratori
syndrom
sar
trypanosoma
cruzi
live
donor
undergo
batteri
serolog
test
tabl
purifi
protein
deriv
ppd
skin
test
tuberculosi
releas
assay
indic
chest
radiograph
test
must
individu
base
uniqu
risk
factor
eg
travel
particular
import
kidney
transplant
recipi
exclus
urinari
tract
infect
includ
yeast
bacteremia
time
donat
recent
recommend
us
public
health
servic
suggest
rescreen
potenti
donor
within
day
donat
use
nat
hiv
hcv
hbv
tuberculosi
mycobacterium
tuberculosi
donor
repres
approxim
report
posttranspl
tuberculosi
case
review
patient
singh
paterson
much
higher
rate
occur
endem
region
activ
diseas
exclud
ppdposit
donor
chest
radiograph
sputum
cultur
chest
comput
tomographi
ct
chest
radiograph
abnorm
urin
acidfast
bacillu
cultur
may
use
ppdposit
kidney
donor
isoniazid
prophylaxi
recipi
consid
untreat
ppdposit
donor
factor
favor
prophylaxi
includ
donor
endem
region
use
highdos
steroid
regimen
highrisk
social
environ
parasit
chaga
diseas
trypanosoma
cruzi
transmit
transplant
endem
area
recent
unit
state
schistosomiasi
infect
strongyloid
stercorali
gener
recipientderiv
issu
though
common
malaria
leishmaniasi
rare
transmit
allograft
viral
infect
cytomegaloviru
ebv
infect
major
risk
factor
develop
ptld
risk
greatest
ebvseroneg
recipi
ebvseroposit
allograft
ie
donor
seroposit
recipi
seroneg
r
situat
common
pediatr
transplant
recipi
adult
coinfect
cmv
receiv
greater
intens
immunosuppress
notabl
tcell
deplet
possibl
belatacept
monitor
consid
atrisk
individu
use
quantit
molecular
assay
eg
polymeras
chain
reaction
ebv
ebv
also
cofactor
lymphoid
malign
vzv
screen
use
identifi
seroneg
individu
histori
chickenpox
shingl
vaccin
transplant
hsv
screen
perform
center
despit
use
antivir
prophylaxi
posttranspl
period
vzv
serolog
statu
particularli
import
children
may
expos
school
antivir
vzv
immunoglobulin
prophylaxi
adult
atyp
present
infect
pneumonia
gastrointestin
diseas
herpesvirus
also
may
reactiv
serv
cofactor
cmv
fungal
infect
endem
region
kaposi
sarcomaassoci
herpesviru
caus
malign
notabl
endem
region
south
america
surround
mediterranean
basin
hbv
surfac
antigen
hbsag
hbv
core
antibodi
hbcab
use
screen
purpos
see
chapter
detail
discuss
posit
hbv
surfac
antibodi
titer
indic
either
vaccin
prior
infect
hbcabigm
posit
suggest
activ
hbv
infect
wherea
igg
posit
suggest
remot
persist
infect
hbsagneg
hbcabiggposit
donor
viral
dna
liver
may
appropri
kidney
donor
hbvinfect
vaccin
renal
recipi
quantit
viral
assay
hbv
obtain
guid
therapi
presenc
hbsagneg
hbcabiggposit
assay
may
falseposit
result
reflect
true
latent
hbv
infect
hcv
infect
gener
progress
rapidli
immunosuppress
cmv
coinfect
see
chapter
detail
discuss
hcvseroposit
kidney
transplant
candid
like
develop
cirrhosi
complic
liver
failur
therapi
hcv
infect
limit
side
effect
standard
therapi
pegyl
ribavirin
increas
transplant
popul
newer
proteas
inhibitor
agent
avail
efficaci
immunosuppress
host
investig
manag
involv
monitor
diseas
progress
quantit
molecular
viral
assay
hcv
rna
intermitt
liver
biopsi
manag
like
chang
newer
hcv
antivir
agent
becom
avail
see
chapter
use
hivinfect
donor
hivinfect
recipi
preclud
unit
state
studi
south
africa
elsewher
progress
untreat
recipi
hiv
infect
rapid
base
current
criteria
donor
may
exclud
base
histor
evid
risk
factor
signific
hiv
infect
confirmatori
test
human
tcell
lymphotrop
viru
htlvi
endem
caribbean
part
asia
japan
progress
htlviassoci
myelopathytrop
spastic
paraparesi
adult
tcell
leukemia
lymphoma
htlvii
similar
htlvi
serolog
less
clearli
associ
diseas
use
organ
donor
gener
avoid
howev
serolog
test
distinguish
two
type
viru
donor
screen
htlv
unit
state
voluntari
west
nile
viru
flaviviru
associ
viral
syndrom
meningoenceph
may
transmit
blood
transfus
organ
transplant
routin
screen
donor
advoc
area
endem
infect
donor
unexplain
chang
mental
statu
recent
viral
ill
neurolog
sign
avoid
pretranspl
period
use
obtain
travel
anim
environment
exposur
histori
updat
immun
counsel
recipi
regard
travel
food
infect
risk
ongo
infect
must
erad
transplant
two
form
infect
pose
special
risk
blood
stream
infect
relat
vascular
access
includ
dialysi
pneumonia
put
patient
high
risk
subsequ
lung
infect
nosocomi
organ
sever
infect
commonli
encount
treat
clear
transplant
infect
ascit
periton
dialysi
fluid
also
must
clear
surgeri
urinari
tract
infect
must
elimin
antibiot
without
nephrectomi
similarli
skin
diseas
threaten
integr
primari
defens
infect
correct
even
requir
initi
immunosuppress
transplant
eg
initi
immunosuppress
treat
psoriasi
eczema
final
histori
one
episod
diverticul
initi
evalu
determin
whether
sigmoid
colectomi
done
transplant
among
import
consider
transplant
recipi
strongyloidiasi
tuberculosi
aid
strongyloid
hyperinfest
syndrom
hemorrhag
enterocol
pneumonia
gramneg
mix
bacteremia
mening
may
emerg
year
transplant
empir
pretransplant
therapi
strongyloidesseroposit
recipi
ivermectin
prevent
infect
incid
activ
tubercul
diseas
occurr
dissemin
infect
secondari
mycobacterium
tuberculosi
higher
transplant
recipi
gener
popul
activ
tubercul
diseas
must
erad
transplant
major
antitubercul
drug
potenti
hepatotox
signific
drug
interact
common
antituberculosi
agent
immunosuppress
agent
patient
activ
infect
endem
region
highrisk
exposur
tuberculosi
therapi
initi
ppdposit
individu
transplant
judgment
may
use
optim
time
treatment
individu
without
evid
activ
pleuropulmonari
diseas
patient
greater
risk
tuberculosi
infect
exposur
includ
individu
prior
histori
activ
tuberculosi
signific
sign
old
tuberculosi
chest
radiograph
recent
tuberculin
reaction
convers
known
exposur
activ
diseas
proteincalori
malnutrit
cirrhosi
immunodefici
live
exposur
eg
shelter
group
hous
mani
patient
receiv
antiretrovir
therapi
hiv
infect
convert
progress
fatal
diseas
chronic
infect
control
complex
regimen
antivir
agent
highli
activ
antiretrovir
therapi
haart
haart
associ
reduc
viral
load
improv
lymphocyt
count
reduc
suscept
opportunist
infect
prehaart
era
organ
transplant
gener
associ
rapid
progress
aid
prolong
diseasefre
surviv
haart
led
howev
reconsider
polici
kidney
transplant
hiv
associ
good
outcom
individu
control
hiv
infect
absenc
hcv
coinfect
manag
requir
experi
immunosuppress
agent
variou
haart
regimen
main
hurdl
drug
interact
proteas
inhibitor
calcineurin
inhibitor
need
full
immuosuppress
despit
hiv
infect
spectrum
infect
immunocompromis
host
quit
broad
given
toxic
antimicrobi
agent
need
rapid
interrupt
infect
earli
specif
diagnosi
essenti
popul
advanc
diagnost
modal
eg
ct
magnet
reson
imag
molecular
microbiolog
techniqu
may
greatli
assist
process
need
invas
diagnost
tool
overemphas
howev
given
diminish
immun
respons
host
frequenc
multipl
simultan
process
invas
diagnosi
often
requir
specif
microbiolog
diagnosi
minim
side
effect
therapi
improv
clinic
respons
initi
empir
therapi
broad
necess
rapid
narrow
antimicrobi
spectrum
data
becom
avail
among
decis
antiinfect
therapi
whether
reduc
intens
immunosuppress
understand
risk
approach
graft
reject
latent
viral
infect
tuberculosi
activ
seen
evid
excess
immunosuppress
rel
host
immun
function
contrast
intercurr
bacteri
fungal
infect
reduct
immunosuppress
reconsid
resolut
infect
demonstr
specif
reduct
chosen
may
depend
organ
isol
eg
corticosteroid
bacteri
infect
similarli
revers
immun
deficit
eg
neutropenia
hypogammaglobulinemia
may
possibl
adjunct
therapi
eg
colonystimul
factor
antibodi
coinfect
viru
cmv
common
requir
addit
therapi
advers
effect
reduc
immun
suppress
infect
best
demonstr
patient
cryptococc
mening
rebound
inflammatori
respons
may
result
worsen
symptom
hydrocephalu
reflect
immun
reconstitut
inflammatori
syndrom
iri
seen
patient
immun
deficit
revers
face
ongo
inflamm
invas
infect
due
cmv
becom
less
common
due
avail
effect
antivir
therapi
diagnost
monitor
assay
viru
tabl
howev
even
latent
infect
lowlevel
replic
import
implic
transplant
outcom
strategi
use
prevent
univers
versu
preemptiv
therapi
monitor
treat
infect
vari
center
manifest
cmv
infect
tradit
term
direct
indirect
effect
accur
term
might
viremiccytopath
effect
cellularimmunolog
effect
common
direct
effect
clinic
syndrom
includ
cmv
syndrom
viremia
associ
fever
neutropenia
syndrom
variabl
featur
infecti
mononucleosi
includ
hepat
nephriti
lymphaden
leukopenia
andor
thrombocytopenia
pneumon
often
difficult
distinguish
appar
benign
secret
gastrointestin
invas
esophag
coliti
gastriti
ulcer
bleed
perfor
hepat
pancreat
myocard
chorioretin
meningoenceph
hemolyt
urem
syndrom
microangiopath
thrombosi
except
chorioretin
direct
clinic
manifest
cmv
infect
usual
occur
month
transplant
absenc
prophylaxi
viremia
symptomat
infect
rare
effect
antivir
prophylaxi
gener
delay
cessat
prophylaxi
develop
associ
intensif
immunosuppress
eg
reject
chorioretin
occur
low
level
viral
replic
gener
later
posttranspl
cours
cellular
immunolog
effect
cmv
infect
discuss
result
suppress
varieti
host
defens
mechan
predispos
secondari
invas
p
jiroveci
candida
aspergillu
speci
bacteri
fungal
pathogen
cmv
infect
also
contribut
risk
graft
reject
ptld
acceler
hcv
coinfect
infect
increas
risk
death
primari
cmv
infect
greatest
risk
infect
set
primari
cmv
infect
seroneg
individu
receiv
graft
latent
infect
seroposit
donor
r
subsequ
reactiv
viru
system
dissemin
patient
becom
virem
absenc
prophylaxi
often
without
symptom
mani
becom
virem
cessat
antivir
prophylaxi
symptomat
late
infect
occur
third
recipi
previous
treat
prophylaxi
primari
cmv
infect
may
also
occur
seroneg
individu
transfus
sexual
contact
commun
diseas
may
sever
allograft
may
privileg
site
viral
replic
major
histocompat
complex
mhc
restrict
virusspecif
cytotox
cell
decreas
abil
elimin
viral
infect
cell
presenc
mhc
mismatch
donor
recipi
reactiv
cmv
infect
reactiv
infect
seroposit
individu
reactiv
endogen
viru
transplant
r
convent
immunosuppress
therapi
use
without
antilymphocyt
antibodi
induct
treatment
approxim
experi
direct
infecti
diseas
syndrom
absenc
prophylaxi
higher
rate
follow
tcell
deplet
therapi
cmv
superinfect
viru
deriv
donor
may
reactiv
set
allograft
seroposit
donor
transplant
seroposit
recipi
r
blood
transfus
even
leukocytereduc
low
rate
transmiss
cmv
infect
observ
gain
import
patient
requir
signific
transfus
periop
set
cmv
activ
occur
result
multipl
factor
includ
intens
immunosuppress
notabl
pulseddos
corticosteroid
amount
viru
graft
use
lytic
tcelldeplet
therapi
coinfect
notabl
herpesvirus
graft
reject
event
share
featur
inflamm
fever
endotheli
activ
injuri
secret
proinflammatori
cytokin
includ
tumor
necrosi
activ
intracellular
transloc
cell
nucleu
activ
cmv
major
immediateearli
promoterenhanc
viral
replic
risk
viral
activ
set
intensifi
immunosuppress
graft
reject
must
link
prophylaxi
notabl
cmv
serostatu
rcombin
alloimmun
respons
carri
effect
injuri
graft
gener
site
greatest
viral
load
system
inflamm
thu
bidirect
linkag
exist
cmv
replic
graft
reject
interest
studi
reink
et
al
show
patient
biopsi
reveal
evid
late
acut
reject
demonstr
respons
antivir
therapi
lowanc
et
al
demonstr
prevent
cmv
infect
also
result
lower
incid
graft
reject
cellular
immunolog
effect
cmv
indirect
effect
may
import
immunocompromis
host
invas
viral
infect
mechan
effect
complex
relat
viral
strategi
evad
host
antivir
respons
allow
human
cmvinfect
antigenpres
cell
travel
throughout
host
spread
viru
clinic
manag
cmv
includ
prevent
treatment
base
understand
caus
cmv
activ
avail
diagnost
techniqu
cmv
cultur
gener
slow
insensit
clinic
util
posit
cmv
cultur
shell
vial
cultur
deriv
respiratori
secret
urin
littl
diagnost
valu
mani
immunosuppress
patient
secret
cmv
absenc
invas
diseas
serolog
test
use
transplant
predict
risk
littl
valu
transplant
defin
clinic
diseas
includ
measur
anticmv
igm
level
seroconvers
gener
delay
seroconvers
cmv
provid
evid
patient
develop
degre
immun
appear
correl
tcell
function
well
antibodi
quantit
intens
cmv
infect
link
risk
infect
transplant
recipi
two
type
quantit
assay
develop
molecular
antigen
detect
assay
antigenemia
assay
semiquantit
fluoresc
assay
circul
neutrophil
stain
cmv
earli
antigen
taken
nonspecif
measur
total
viral
burden
bodi
molecular
assay
direct
dna
polymeras
chain
reaction
hybrid
captur
amplif
assay
highli
specif
sensit
detect
viremia
commonli
use
assay
includ
plasmabas
polymeras
chain
reaction
test
wholeblood
hybrid
captur
assay
wholeblood
plasmabas
assay
directli
compar
assay
perform
differ
laboratori
often
discord
world
health
organ
standard
creat
use
harmon
assay
center
highest
viral
load
often
associ
tissueinvas
diseas
lowest
asymptomat
cmv
infect
viral
load
cmv
syndrom
vari
either
assay
use
manag
advent
quantit
assay
diagnosi
manag
cmv
infect
allow
noninvas
diagnosi
mani
patient
two
import
except
neurolog
diseas
includ
chorioretin
gastrointestin
diseas
includ
invas
coliti
gastriti
syndrom
cmv
assay
often
neg
diagnosi
gastrointestin
cmv
diseas
demonstr
cmv
inclus
tissu
andor
immunohistolog
cmv
antigen
remain
essenti
central
role
assay
illustr
approach
manag
cmv
risk
tabl
schedul
screen
link
risk
infect
highrisk
patient
r
r
antilymphocyt
globulin
complet
prophylaxi
monthli
screen
perform
ensur
absenc
infect
month
patient
treat
cmv
infect
assay
provid
endpoint
therapi
initi
prophylaxi
prevent
cmv
infect
must
individu
immunosuppress
regimen
patient
tabl
two
strategi
commonli
use
cmv
preventionunivers
prophylaxi
preemptiv
therapi
univers
prophylaxi
involv
give
antivir
therapi
atrisk
patient
begin
immedi
transplant
defin
period
preemptiv
therapi
quantit
assay
use
monitor
patient
predefin
interv
gener
weekli
week
detect
earli
diseas
posit
assay
result
therapi
preemptiv
therapi
incur
extra
cost
monitor
coordin
outpati
care
reduc
cost
drug
inher
toxic
prophylaxi
possibl
advantag
prevent
cmv
infect
period
greatest
risk
also
diminish
infect
secondari
ebv
indirect
effect
cmv
ie
graft
reject
opportunist
infect
also
may
reduc
routin
prophylaxi
practic
neither
univers
prophylaxi
preemptiv
therapi
perfect
mani
center
use
combin
approach
univers
prophylaxi
highestrisk
recipi
rand
r
tcell
deplet
preemptiv
therapi
other
infrequ
breakthrough
diseas
ganciclovir
resist
observ
approach
given
risk
invas
infect
patient
risk
primari
infect
cmv
r
seroposit
patient
receiv
deplet
antitlymphocyt
antibodi
gener
given
prophylaxi
month
transplant
group
candid
preemptiv
therapi
appropri
monitor
system
place
patient
complianc
good
current
data
support
use
univers
prophylaxi
preemptiv
therapi
howev
prevent
indirect
effect
cmv
infect
includ
ptld
opportunist
infect
allograft
reject
mortal
increasingli
late
diseas
observ
complet
prophylaxi
thu
monitor
may
use
prophylaxi
rate
late
diseas
vari
thought
high
rrecipi
observ
suggest
valu
month
prophylaxi
rrenal
recipi
impact
studi
option
cmv
prophylaxi
includ
valganciclovir
mg
oral
daili
oral
ganciclovir
g
three
time
daili
intraven
ganciclovir
mgkg
daili
highdos
oral
valacyclovir
g
four
time
daili
correct
renal
function
valganciclovir
ganciclovir
associ
neutropenia
howev
dose
reduct
risk
breakthrough
viremia
emerg
viral
resist
prophylaxi
reiniti
treatment
antilymphocyt
therapi
given
chang
renal
function
transplant
cost
medic
mani
regimen
employ
lower
dose
valganciclovir
regimen
coupl
monitor
assur
efficaci
complet
treatment
cmv
diseas
see
mani
center
initi
cours
secondari
prophylaxi
month
altern
period
virolog
monitor
period
treatment
standard
care
treat
invas
cmv
diseas
week
intraven
ganciclovir
mgkg
twice
daili
dosag
adjust
renal
dysfunct
quantit
assay
cmv
neg
patient
mild
moder
sever
symptom
valganciclovir
mg
po
twice
daili
correct
renal
function
may
use
altern
symptomat
patient
slow
respond
therapi
seroneg
addit
month
cmv
hyperimmun
globulin
seroneg
individu
mgkgdose
iv
monthli
may
use
costli
uncertain
benefit
relaps
occur
primarili
seroneg
patient
high
viral
burden
treat
achiev
neg
quantit
assay
gastrointestin
diseas
treat
oral
regimen
repeat
endoscopi
consid
ensur
clearanc
infect
practic
reason
initi
therapi
intraven
ganciclovir
monitor
weekli
assur
respons
treat
monitor
neg
patient
may
benefit
month
oral
valganciclovir
mg
daili
base
creatinin
clearanc
administ
secondari
prophylaxi
complet
intraven
therapi
approach
result
rare
symptomat
relaps
associ
uncommonli
emerg
antivir
resist
may
worth
measur
formal
creatinin
clearanc
assur
adequ
dose
incid
ganciclovir
resist
cmv
gener
low
risk
resist
greatest
rrecipi
higher
viral
load
receiv
inadequ
dose
prophylact
therapeut
ganciclovir
intens
immunosuppress
includ
antilymphocyt
antibodi
induct
prolong
antivir
prophylaxi
clinic
patient
viral
load
clinic
syndrom
fail
respond
appropri
therapi
includ
reduct
immunosuppress
day
genet
resist
test
use
manag
resist
cmv
infect
mutat
viral
thymidin
kinas
dna
polymeras
gene
confer
ganciclovir
resist
common
mutat
gene
respond
higher
dose
intraven
ganciclovir
combin
mutat
may
manifest
highlevel
resist
ganciclovir
altern
therapi
avail
intraven
form
includ
foscarnet
cidofovir
foscarnet
activ
mani
ganciclovirresist
strain
cmv
although
associ
mark
magnesium
potassium
wast
seizur
notabl
calcineurin
inhibitor
therapi
renal
toxic
cidofovir
may
also
use
often
incur
signific
nephrotox
ocular
toxic
liposom
cidofovir
investig
mutat
may
caus
resist
foscarnet
cidofovir
depend
natur
mutat
multipl
cours
antivir
therapi
may
need
cure
resist
cmv
infect
given
toxic
avail
medic
sever
investig
drug
studi
may
alter
recommend
therapi
antiviralresist
cmv
combin
therapi
ganciclovir
foscarnet
may
use
addit
hyperimmun
globulin
center
tri
reduc
overal
immunosuppress
cours
therapi
altern
agent
includ
dihydroorot
dehydrogenas
inhibitor
leflunamid
approv
immunosuppress
treatment
rheumatolog
diseas
use
incident
activ
cmv
possibl
bk
polyomaviru
ebv
ubiquit
herpesviru
infect
b
lymphocyt
immunosuppress
transplant
recipi
primari
ebv
infect
relaps
absenc
antivir
immun
caus
mononucleosistyp
syndrom
gener
manifest
lymphocytosi
b
cell
without
lymphadenopathi
pharyng
mening
hepat
pancreat
also
observ
remittingrelaps
ebv
infect
common
children
may
reflect
interplay
evolv
antivir
immun
immunosuppress
regardless
mode
express
syndrom
suggest
rel
overimmunosuppress
ebv
also
play
central
role
pathogenesi
ptld
ptld
repres
spectrum
diseas
benign
bcell
mononucleosislik
syndrom
monomorph
bcell
lymphoma
well
tumor
tcell
natur
killer
cell
nullcel
origin
figur
clearli
defin
risk
factor
ptld
primari
ebv
infect
increas
risk
ptld
ptld
may
occur
absenc
ebv
infect
seroposit
patient
role
ebv
pathogenesi
nonbcel
tumor
less
clear
risk
factor
includ
cmv
coinfect
tcell
deplet
therapi
durat
immunosuppress
adult
older
age
posttranspl
nonhodgkin
lymphoma
common
complic
solidorgan
transplant
lymphoma
constitut
tumor
among
adult
transplant
recipi
children
mortal
mani
death
associ
allograft
failur
withdraw
immunosuppress
treatment
malign
compar
gener
popul
ptld
increas
extranod
involv
poor
respons
convent
therapi
poor
outcom
spectrum
diseas
broad
rang
benign
polyclon
bcell
infecti
mononucleosislik
diseas
malign
monoclon
lymphoma
diseas
bcell
origin
although
tcell
natur
killer
cell
null
cell
tumor
describ
ebvneg
ptld
b
describ
tcell
ptld
shown
allograft
thought
reject
viral
infect
ptld
late
year
transplant
often
ebvneg
adult
clinic
present
ebvassoci
ptld
vari
wide
includ
unexplain
fever
fever
unknown
origin
viremia
mononucleosistyp
syndrom
fever
malais
without
pharyng
tonsil
often
diagnos
incident
tonsillectomi
specimen
often
lymphadenopathi
observ
gastrointestin
bleed
obstruct
perfor
abdomin
mass
lesion
infiltr
diseas
allograft
hepatocellular
pancreat
dysfunct
central
nervou
system
cn
mass
lesion
diagnosi
serolog
test
use
diagnosi
acut
ebv
infect
ptld
transplant
quantit
ebv
viral
load
test
requir
diagnosi
manag
ptld
serial
assay
use
individu
patient
specif
viral
load
measur
assay
standard
directli
compar
center
data
suggest
assay
use
unfraction
whole
blood
prefer
plasma
sampl
ebv
viral
load
surveil
diagnosi
ptld
may
suggest
presenc
compat
clinic
syndrom
demonstr
ebv
viral
load
ebv
viral
load
whole
blood
plasma
appear
similar
controversi
exist
respect
prefer
sampl
type
viral
load
monitor
nonstandard
result
may
compar
clinic
laboratori
trend
individu
patient
time
use
singl
assay
use
demonstr
ebvspecif
nucleic
acid
tissu
may
diagnos
ebvassoci
ptld
rna
situ
hybrid
ebvencod
small
nuclear
rna
sensit
detect
viral
dna
ebv
latent
antigen
detect
immunohistochemistri
clinic
manag
depend
stage
diseas
polyclon
form
particularli
children
reestablish
immun
function
may
suffic
caus
ptld
regress
stage
possibl
antivir
therapi
might
util
given
viremia
role
ebv
cmv
present
immunosuppress
agent
progress
diseas
extranod
monoclon
malign
form
reduct
immunosuppress
may
use
altern
therapi
often
requir
kidney
transplant
failur
regress
signific
reduct
immunosuppress
may
suggest
need
sacrific
allograft
patient
surviv
combin
antibcel
therapi
rituximab
chemotherapi
chop
cyclophosphamid
hydroxydaunomycin
vincristin
prednison
irradi
especi
cn
tumor
adopt
immunotherapi
stimul
cell
use
polyomavirus
identifi
transplant
recipi
associ
nephropathi
ureter
obstruct
bk
viru
associ
demyelin
diseas
brain
jc
viru
similar
progress
multifoc
leukoencephalopathi
pml
aid
adult
level
seropreval
bk
viru
resid
latenc
renal
tubular
epitheli
cell
jc
viru
also
isol
renal
tissu
seem
prefer
tropism
neural
tissu
reactiv
occur
immunodefici
immunosuppress
tissu
injuri
eg
ischemiareperfus
bk
viru
associ
rang
clinic
syndrom
immunocompromis
host
includ
viruria
viremia
ureter
ulcer
stenosi
hemorrhag
cystiti
activ
infect
renal
allograft
associ
progress
loss
graft
function
bk
nephropathi
approxim
rang
kidney
transplant
recipi
refer
pvan
bk
nephropathi
rare
recogn
recipi
extraren
organ
clinic
present
diseas
usual
steril
pyuria
reflect
shed
infect
tubular
ureter
epitheli
cell
cell
contain
sheet
viru
detect
urin
cytolog
decoy
cell
case
patient
present
diminish
renal
allograft
function
ureter
stenosi
obstruct
patient
etiolog
decreas
renal
function
must
care
evalu
eg
mechan
obstruct
drug
toxic
pyelonephr
reject
thrombosi
recurr
diseas
choic
must
made
increas
immunosuppress
treat
suspect
graft
reject
reduc
immunosuppress
allow
immun
system
control
infect
patient
bk
nephropathi
treat
increas
immunosuppress
high
incid
graft
loss
reduc
immunosuppress
may
stabil
renal
allograft
function
risk
graft
reject
risk
factor
bk
nephropathi
poorli
defin
studi
implic
highdos
immunosuppress
particularli
tcell
deplet
tacrolimu
mycophenol
mofetil
pulsedos
steroid
treatment
graft
reject
ischemiareperfus
injuri
increas
number
hla
mismatch
donor
recipi
intens
viremia
pathogenesi
diseas
role
specif
immunosuppress
agent
confirm
greatest
incid
bk
nephropathi
center
intens
immunosuppress
regimen
screen
prevent
diagnosi
bk
viru
infect
gener
asymptomat
renal
tubular
cell
injuri
pvan
reflect
rise
serum
creatinin
center
develop
screen
program
document
earli
diseas
use
urin
cytolog
detect
presenc
infect
decoy
cell
urin
approxim
sensit
bk
viru
infect
low
predict
valu
detect
urin
bk
viru
electron
microscopi
urin
bk
viral
dna
load
greater
log
geqml
bk
viru
gene
mrna
log
copiesng
total
urin
rna
use
diagnost
patient
bk
nephropathi
higher
plasma
viral
load
bk
viru
copi
per
ml
plasma
p
posit
predict
valu
neg
predict
valu
compar
patient
without
diseas
high
serum
bk
viral
load
consid
basi
reduct
immunosuppress
especi
serum
creatinin
risen
howev
diagnosi
made
demonstr
bk
viru
cytopath
chang
cellular
infiltr
consist
diagnosi
interstiti
nephriti
allograft
immunohistolog
bk
viru
protein
situ
hybrid
bk
viru
nucleic
acid
renal
biopsi
semiquantit
score
system
histolog
chang
pvan
immunohistochemistri
crossreact
antibodi
larg
tantigen
simian
viru
antibodi
bk
viru
agnoprotein
use
pvan
character
intranuclear
polyomaviru
inclus
bodi
tubular
epitheli
glomerular
cell
fibrosi
often
promin
occasion
calcif
pvan
often
focal
falseneg
biopsi
case
graft
reject
may
accompani
pvan
complic
diagnosi
manag
recommend
regard
screen
bk
viru
infect
vari
gener
suggest
test
everi
month
first
year
transplant
least
annual
year
urinari
test
bk
viru
cytolog
decoy
cell
urin
bk
viru
load
log
geqml
adequ
screen
patient
high
urinari
bk
viral
load
requir
test
plasma
bk
viru
dna
screen
also
perform
use
plasma
bk
viru
dna
load
patient
plasma
bk
viral
dna
load
geqml
duplic
test
week
apart
presumpt
diagnosi
pvan
made
immunosuppress
reduc
see
screen
perform
plasma
viral
load
interv
screen
assay
reduc
monthli
first
month
posttranspl
reflect
reduc
time
perman
renal
injuri
patient
circul
viremia
compar
urinari
excret
treatment
accept
treatment
pvan
reduct
intens
immun
suppress
use
monitor
respons
maneuv
use
plasma
viral
load
measur
despit
controversi
reason
reduc
dose
calcineurin
inhibitor
antimetabolit
stepwis
fashion
monitor
bk
viru
plasma
load
given
toxic
calcineurin
inhibitor
tubular
cell
role
injuri
activ
bk
viru
well
need
antibk
tcell
activ
agent
includ
initi
reduct
gener
target
includ
tacrolimu
trough
level
ngml
cyclosporin
trough
level
ngml
sirolimu
trough
level
ngml
andor
mycophenol
mofetil
daili
dose
equival
mg
regardless
approach
renal
function
least
time
per
week
drug
level
viral
load
altern
week
must
monitor
care
reduct
rebiopsi
may
need
poor
respons
use
adjunct
antivir
therapi
remain
controversi
center
advoc
use
cidofovir
bk
nephropathi
low
dose
mgkg
everi
week
signific
renal
toxic
may
observ
agent
leflunomid
immunosuppress
use
rheumatoid
arthriti
fluoroquinolon
antibk
activ
use
agent
prompt
consult
clinician
expert
area
replet
serum
immunoglobulin
treatment
intraven
immunoglobulin
also
use
anecdot
success
patient
retransplant
success
pvan
patient
fail
allograft
possibl
reflect
immun
develop
subsequ
reduct
immun
suppress
center
allow
retransplant
immunosuppress
discontinu
period
month
bk
viru
undetect
blood
low
urin
surgic
remov
allograft
protect
futur
bk
infect
pvan
may
need
immunosuppress
reduc
doubl
transplant
allosensit
andor
elev
viral
load
persist
futur
measur
bk
virusspecif
cellular
immun
discontinu
immunosuppress
may
help
determin
optim
time
retransplant
infect
cn
jc
polyomaviru
observ
uncommonli
transplant
recipi
pml
figur
infect
may
present
focal
neurolog
deficit
seizur
well
slowli
progress
neurolog
lesion
may
progress
death
follow
extens
demyelin
pml
may
confus
calcineurin
neurotox
may
respond
reduct
drug
level
proven
therapi
exist
although
reduct
immunosuppress
commonli
employ
analog
immun
reconstitut
aid
patient
pml
addit
endem
mycos
transplant
recipi
risk
opportunist
infect
varieti
fungal
agent
import
candida
aspergillu
cryptococcu
neoforman
common
fungal
pathogen
transplant
patient
candida
nonalbican
strain
mucocutan
candid
infect
eg
oral
thrush
esophag
infect
cutan
infect
intertrigin
site
candid
vagin
common
diabet
highdos
steroid
therapi
broadspectrum
antibacteri
therapi
infect
usual
treatabl
correct
underli
metabol
abnorm
topic
therapi
clotrimazol
nystatin
tabl
special
problem
kidney
transplant
recipi
candiduria
includ
asymptomat
patient
notabl
individu
poor
bladder
function
obstruct
fungal
ball
develop
ureteropelv
junction
result
obstruct
uropathi
ascend
pyelonephr
possibl
system
dissemin
singl
posit
cultur
result
candida
speci
blood
specimen
necessit
system
antifung
therapi
find
carri
signific
risk
dissemin
invas
popul
invas
aspergillosi
medic
emerg
transplant
recipi
portal
entri
lung
sinus
patient
skin
remain
predomin
speci
depend
clinic
center
prior
exposur
soil
construct
site
patholog
hallmark
invas
aspergillosi
blood
vessel
invas
account
three
clinic
characterist
infect
tissu
infarct
hemorrhag
system
dissemin
metastat
invas
earli
cours
transplant
cn
involv
fungal
infect
often
due
aspergillu
year
later
transplant
fungi
zygomycet
dematiac
fungi
becom
promin
drug
choic
document
aspergillu
infect
voriconazol
despit
signific
interact
calcineurin
inhibitor
rapamycin
liposom
amphotericin
equal
effect
altern
combin
therapi
studi
surgic
debrid
usual
essenti
success
clearanc
invas
infect
cn
infect
transplant
recipi
may
result
broad
spectrum
organ
infect
often
metastat
cn
blood
stream
lung
viral
etiolog
includ
cmv
nodular
angiiti
hsv
meningoenceph
jc
viru
progress
multifoc
leukoencephalopathi
vzv
local
epidemiolog
west
nile
viru
eastern
equin
enceph
also
must
consid
common
bacteri
infect
addit
pneumococcu
includ
lyme
diseas
listeria
monocytogen
tuberculosi
nocardia
occasion
salmonella
brain
abscess
epidur
abscess
observ
may
particularli
problemat
secondari
methicillinresist
staphylococcu
aureu
penicillinresist
pneumococcu
quinoloneresist
streptococci
note
earlier
fungi
may
metastat
lung
aspergillu
cryptococcu
also
may
spread
sinus
mucoracea
skin
dematiacea
blood
stream
histoplasma
pseudallescheria
scedosporium
fusarium
parasit
includ
toxoplasma
gondii
strongyloid
stercorali
given
spectrum
etiolog
precis
diagnosi
essenti
tabl
reason
empir
regimen
would
treat
pneumococcu
haemophilu
influenza
ceftriaxon
vancomycin
listeria
ampicillin
cryptococcu
fluconazol
amphotericin
hsv
acyclovir
await
data
lumbar
punctur
blood
cultur
radiograph
studi
noninfecti
etiolog
includ
calcineurin
inhibitor
toxic
lymphoma
metastat
cancer
includ
differenti
diagnosi
molecular
assay
hsv
biopsi
noninfecti
etiolog
may
need
diagnosi
cryptococc
infect
rare
seen
transplant
recipi
month
transplant
rel
intact
transplant
recipi
common
present
cryptococc
infect
asymptomat
pulmonari
nodul
often
activ
organ
present
chronic
neerdowel
patient
pneumonia
mening
common
skin
involv
site
tissu
injuri
cathet
prostat
bone
also
report
cryptococcosi
suspect
transplant
recipi
present
unexplain
headach
especi
accompani
fever
decreas
state
conscious
failur
thrive
unexplain
focal
skin
diseas
requir
biopsi
cultur
patholog
evalu
month
transplant
diagnosi
often
achiev
serum
cryptococc
antigen
detect
patient
lumbar
punctur
cell
count
cultur
india
ink
prepar
cryptococc
antigen
studi
figur
initi
treatment
best
liposom
amphotericin
monitor
serum
level
follow
highdos
fluconazol
cryptococc
antigen
clear
blood
cerebrospin
fluid
lifetim
prophylaxi
need
iri
may
requir
adjunct
use
corticosteroid
acut
phase
cn
cryptococc
infect
iri
scar
may
caus
obstruct
increas
cerebrospin
fluid
pressur
hydrocephalu
strongyloid
stercorali
stercorali
infect
may
activ
year
initi
exposur
immunosuppress
therapi
reactiv
result
either
diarrheal
ill
parasit
migrat
hyperinfest
syndrom
character
hemorrhag
enterocol
hemorrhag
pneumonia
dissemin
infect
accompani
usual
gramneg
bacteremia
mening
patient
tropic
area
southeastern
unit
state
screen
strongyloid
igg
serolog
prior
transplant
treat
ivermectin
preemptiv
seroposit
spectrum
potenti
pathogen
lung
transplant
recipi
broad
gener
concept
worth
consider
infect
transplant
invas
diagnost
techniqu
often
necessari
specif
microbiolog
diagnosi
avoid
unnecessari
toxic
antimicrobi
agent
select
optim
therapi
depress
inflammatori
respons
immunocompromis
transplant
patient
may
greatli
modifi
delay
appear
pulmonari
lesion
radiograph
focal
multifoc
consolid
acut
onset
like
caus
bacteri
infect
similar
multifoc
lesion
subacut
chronic
progress
like
secondari
fungi
tuberculosi
nocardi
infect
larg
nodul
usual
sign
fungal
nocardi
infect
particularli
subacut
chronic
onset
subacut
diseas
diffus
abnorm
either
peribronchovascular
type
miliari
micronodul
usual
caus
virus
especi
cmv
pneumocysti
addit
clue
found
examin
pulmonari
lesion
cavit
suggest
necrot
infect
may
caus
fungi
aspergillu
mucoracea
nocardia
staphylococcu
certain
gramneg
bacilli
commonli
klebsiella
pneumonia
pseudomona
aeruginosa
ct
chest
use
chest
radiograph
neg
radiograph
find
subtl
nonspecif
ct
also
essenti
definit
extent
diseas
process
discern
possibl
simultan
process
superinfect
select
optim
invas
techniqu
achiev
patholog
diagnosi
pneumocysti
jiroveci
pneumonia
pcp
greatest
first
month
transplant
period
increas
immunosuppress
patient
receiv
trimethoprimsulfamethoxazol
altern
drug
prophylaxi
transplant
center
report
incid
pneumocysti
pneumonia
approxim
first
month
transplant
continu
risk
infect
three
overlap
group
transplant
recipi
recipi
requir
higher
normal
level
immunosuppress
prolong
period
poor
allograft
function
chronic
reject
recipi
chronic
cmv
infect
recipi
undergo
treatment
increas
level
immunodefici
cancer
chemotherapi
neutropenia
secondari
drug
toxic
expect
mortal
secondari
pneumocysti
pneumonia
increas
patient
cyclosporin
compar
immunocompromis
host
hallmark
infect
result
pcp
presenc
mark
hypoxemia
dyspnea
cough
pauciti
physic
radiolog
find
transplant
recipi
pneumocysti
pneumonia
gener
acut
subacut
develop
atyp
pneumocysti
infect
radiograph
clinic
may
seen
patient
coexist
pulmonari
infect
develop
diseas
receiv
prophylaxi
secondchoic
agent
eg
pentamidin
atovaquon
patient
outsid
usual
period
greatest
risk
p
carinii
jiroveci
pneumonia
may
present
indol
diseas
may
radiograph
confus
heart
failur
patient
diagnosi
often
made
invas
procedur
role
rapamycin
therapi
clinic
present
unknown
numer
patient
identifi
interstiti
pneumon
receiv
rapamycin
syndrom
may
occur
presenc
absenc
concomit
infect
adenoviru
respiratori
syncyti
viru
pneumocysti
diagnosi
therapi
prophylaxi
characterist
hypoxemia
pneumocysti
pneumonia
produc
broad
alveolararteri
partial
pressur
oxygen
gradient
level
serum
lactat
dehydrogenas
elev
patient
pneumocysti
pneumonia
iuml
mani
diffus
pulmonari
process
also
increas
serum
lactat
dehydrogenas
level
howev
diagnost
pattern
exist
pneumocysti
pneumonia
routin
chest
radiograph
chest
radiograph
may
entir
normal
develop
classic
pattern
perihilar
interstiti
groundglass
infiltr
figur
chest
ct
scan
sensit
diffus
interstiti
nodular
pattern
routin
radiograph
clinic
radiolog
manifest
p
carinii
jiroveci
pneumonia
virtual
ident
manifest
cmv
clinic
challeng
determin
whether
pathogen
present
signific
extrapulmonari
diseas
uncommon
transplant
recipi
bronchoalveolar
lavag
may
help
earli
therapi
trimethoprimsulfamethoxazol
prefer
kidney
transplant
patient
toler
fulldos
trimethoprimsulfamethoxazol
prolong
period
reflect
elev
creatinin
trimethoprim
compet
secret
kidney
toxic
sulfa
agent
renal
allograft
hydrat
gradual
initi
therapi
may
help
altern
therapi
less
desir
use
success
includ
intraven
pentamidin
atovaquon
clindamycin
primaquin
pyrimethamin
trimetrex
although
reduct
intens
immunosuppress
gener
consid
part
antiinfect
therapi
transplant
use
short
cours
adjunct
steroid
gradual
taper
gener
use
import
prevent
pneumocysti
infect
overemphas
lowdos
trimethoprimsulfamethoxazol
well
toler
use
absenc
concret
data
show
true
allergi
interstiti
nephriti
altern
prophylact
strategi
includ
dapson
atovaquon
inhal
intraven
pentamidin
less
effect
trimethoprim
sulfamethoxazol
use
patient
signific
allergi
sulfa
drug
trimethoprimsulfamethoxazol
effect
agent
prevent
infect
caus
p
carinii
jiroveci
advantag
trimethoprimsulfamethoxazol
includ
increas
efficaci
lower
cost
avail
oral
prepar
possibl
protect
organ
includ
gondii
isospora
belli
cyclospora
cayetanensi
nocardia
asteroid
common
urinari
respiratori
gastrointestin
bacteri
pathogen
altern
agent
lack
spectrum
activ
major
urinari
tract
infect
occur
first
year
kidney
transplant
subset
patient
recurr
diseas
may
suffer
pyelonephr
bacteremia
urinari
tract
infect
beyond
month
transplant
associ
reduc
renal
graft
surviv
increas
mortal
risk
urinari
tract
infect
kidney
transplant
increas
women
prolong
bladder
catheter
increas
intens
immunosuppress
recipi
deceas
donor
graft
possibl
vesicoureter
reflux
risk
vesicoureter
reflux
depend
part
technic
approach
implant
uret
taken
surgeri
risk
candiduria
particular
increas
patient
receiv
prior
antimicrobi
therapi
neurogen
bladder
indwel
urethr
cathet
intens
care
unit
kidney
transplant
recipi
bacteriuria
asymptomat
pain
pyelonephr
repres
transmur
infect
local
inflamm
outsid
denerv
allograft
caus
perceiv
allograft
tender
major
caus
organ
includ
gramneg
bacilli
escherichia
coli
klebsiella
pseudomona
enterobact
proteu
well
gramposit
larg
enterococci
fungi
candida
speci
group
may
manifest
import
antimicrobi
resist
therapi
base
suscept
pattern
determin
therapi
guid
presenc
absenc
structur
abnorm
obstruct
delay
bladder
empti
well
microbiolog
infect
thu
imag
ultrasound
exclud
hydronephrosi
well
cultur
obtain
patient
upper
tract
infect
initi
empir
therapi
includ
antimicrobi
agent
use
previous
prophylaxi
possibl
use
prior
episod
infect
given
risk
develop
antimicrobi
resist
spectrum
agent
narrow
base
suscept
data
shortcours
therapi
recommend
treatment
uncompl
urinari
tract
infect
transplant
resolut
infect
demonstr
minimum
effect
agent
upper
tract
diseas
least
week
therapi
may
requir
intraven
therapi
initi
asymptomat
candiduria
treat
patient
renal
allograft
although
data
limit
fluconazol
mg
oral
per
day
day
upper
tract
diseas
candida
speci
suggest
obstruct
requir
intens
therapi
fluconazol
mg
daili
week
echinocandin
use
treatment
urinari
tract
infect
achiev
poor
concentr
urinari
tract
remov
stent
cathet
gener
requir
resolut
urinari
tract
infect
prevent
urinari
tract
infect
dramat
alter
routin
use
trimethoprim
sulfamethoxazol
advantag
prevent
pneumocysti
pneumonia
well
urinari
tract
infect
infect
trimethoprimsulfamethoxazol
given
month
year
post
kidney
transplant
gener
effect
absenc
instrument
obstruct
recent
studi
address
whether
chang
ecolog
bacteria
reduc
efficaci
prophylaxi
patient
intoler
trimethoprim
sulfamethoxazol
fluoroquinolon
may
use
addit
anoth
agent
pcp
atovaquon
dapson
transplant
infecti
diseas
increasingli
character
abil
monitor
prevent
infect
base
prophylaxi
new
antimicrobi
agent
vaccin
despit
signific
advanc
infect
pose
lifethreaten
challeng
mani
recipi
futur
increas
avail
pathogenspecif
immun
function
test
enhanc
screen
donor
recipi
better
understand
risk
factor
genet
polymorph
combin
advanc
transplant
immunosuppress
reduc
risk
infect
still
